Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22447816 | 1.00 | TSHR (0.35) | TSHRALDH1A1HSD11B1SLC6A3SLC6A4 | |
| SCHEMBL14231468 | 0.97 | TSHR (0.37) | TSHRSLC6A3SLC6A4 | |
| SCHEMBL537100 | 0.94 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL12265272 | 0.94 | — | — | |
| SCHEMBL1555768 | 0.94 | — | — | |
| SCHEMBL10747441 | 0.94 | ALDH1A1 (0.32) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1568533 | 0.92 | TSHR (0.33) | TSHR | |
| SCHEMBL13762475 | 0.91 | TSHR (0.30) | TSHR | |
| SCHEMBL22483057 | 0.88 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL13378745 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800743-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190100496-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800743-B2 | Arginine methyltransferase inhibitors and uses thereof | PRMT1, PRMT3, PRMT5 | TSHR 3035/4885ALDH1A1 686/4885HSD11B1 567/4885 |
| US-20190100496-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | TSHR 3035/4885ALDH1A1 686/4885HSD11B1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.